Melanoma News and Research

Latest Melanoma News and Research

Chemotherapy plus immunotherapy can enhance anti-tumor effects in patients with advanced cancer

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and Tianjin Medical University Cancer Institute and Hospital in China have discovered that combining chemotherapy drugs and immunotherapy cancer vaccines results in an enhanced anti-tumor effect.

10 Oct 2012

Patient navigation services help vulnerable patients get timely cancer care

Researchers at Boston Medical Center (BMC) have shown that patient navigation services help decrease the time to diagnosis for female patients who have received an abnormal result from a breast or cervical cancer screening.

10 Oct 2012

Without B-Raf and C-Raf proteins mice's fur turns white

These proteins are required for melanocyte stem cell self-maintenance and, as such, correct pigmentation throughout the mice's life span. Without these two proteins, the mice's fur turns white. Their research is published in the review 'Cell Report' and paves the way for serious possibilities in terms of stopping the formation of melanomas, tumours that originate from melanocyte cells.

6 Oct 2012

Transplant recipients and lymphoma patients far likelier to develop melanoma

Melanoma is on the rise nationally, and transplant recipients and lymphoma patients are far likelier than the average person to get that form of skin cancer and to die from it, a Mayo Clinic review has found.

5 Oct 2012

CINJ physicians named among 2012 list of U.S. News Top Doctors

Several physicians at The Cancer Institute of New Jersey (CINJ), who are faculty members at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, have been named as a 'Top Doctor' by U.S. News & World Report.

5 Oct 2012

Loyola launches experimental immune system therapy clinical trial for melanoma in the Midwest

Loyola University Medical Center has launched the first clinical trial in the Midwest of an experimental melanoma treatment that genetically engineers a patient's immune system to fight the deadly cancer.

2 Oct 2012

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.

1 Oct 2012

Drug combinations show promise against metastatic melanoma

Promising new data on drug combinations to treat metastatic melanoma are presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

29 Sep 2012

JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

Sensus Healthcare is pleased to announce the acceptance and publication of the most comprehensive study to date on treating Non Melanoma Skin Cancer (NMSC) with superficial radiotherapy (SRT) in the Journal of the American Academy of Dermatology (JAAD).

29 Sep 2012

Provectus amends and expands protocol for PV-10 Phase 1 hepatocellular carcinoma study

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that it has amended and expanded the scope of the protocol PV-10-LC-01, "A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant."

28 Sep 2012

Broad spectrum sunscreens needed to block UVB and UVA

Writing in the latest edition of Australian Prescriber, Associate Professor Jane Hanrahan from the Faculty of Pharmacy, University of Sydney writes that UVB is the cause of sunburn, but UVA can be more damaging to the skin. It is therefore best to use broad spectrum sunscreens that block both wavebands.

28 Sep 2012

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."

27 Sep 2012

Young women with BRCA mutations feel differently about options for relationships, careers

A study published in the October issue of the American Journal of Nursing (AJN) found that young women who learn they have BRCA1 and BRCA2 gene mutations felt differently about options for relationships, treatment, childbearing and careers.

26 Sep 2012

OncoSec establishes UW as second enrolling site for OMS-I100 Phase II metastatic melanoma trial

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that it has established the University of Washington (UW) as the second enrolling site for its Phase II metastatic melanoma clinical trial (OMS-I100).

25 Sep 2012

Mailed sun protection kits lead to higher frequency of sun protective behaviors

A blistering sunburn during childhood or adolescence more than doubles the adult risk of skin cancer. The accumulation of long-term sun exposure may be equally dangerous.

24 Sep 2012

BioAlliance, Vestiq enter licensing agreement to commercialize Oravig in the US

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the execution of the licensing agreement with Vestiq Pharmaceuticals to commercialize Oravig in the United States for the treatment of oropharyngeal candidiasis in adults.

24 Sep 2012

MD Anderson introduces Moon Shots Program to reduce cancer deaths

The University of Texas MD Anderson Cancer Center announces the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.

21 Sep 2012

ChromaDex announces findings from pTeroPure Phase 2/3 trial on high blood pressure

ChromaDex Corporation announced today findings from a Phase 2/3 trial at the University of Mississippi Medical Center showing its patented nutritional ingredient pTeroPure (pterostilbene) significantly reduced blood pressure in adults.

21 Sep 2012

Melanoma News and Research

Latest Melanoma News and Research

Chemotherapy plus immunotherapy can enhance anti-tumor effects in patients with advanced cancer

Patient navigation services help vulnerable patients get timely cancer care

Without B-Raf and C-Raf proteins mice's fur turns white

Transplant recipients and lymphoma patients far likelier to develop melanoma

CINJ physicians named among 2012 list of U.S. News Top Doctors

Loyola launches experimental immune system therapy clinical trial for melanoma in the Midwest

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Drug combinations show promise against metastatic melanoma

Synta announces results from ganetespib Phase 2b trial on NSCLC

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

Provectus amends and expands protocol for PV-10 Phase 1 hepatocellular carcinoma study

Broad spectrum sunscreens needed to block UVB and UVA

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Young women with BRCA mutations feel differently about options for relationships, careers

OncoSec establishes UW as second enrolling site for OMS-I100 Phase II metastatic melanoma trial

Mailed sun protection kits lead to higher frequency of sun protective behaviors

BioAlliance, Vestiq enter licensing agreement to commercialize Oravig in the US

MD Anderson introduces Moon Shots Program to reduce cancer deaths

ChromaDex announces findings from pTeroPure Phase 2/3 trial on high blood pressure

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in